biotech
Hansa Biopharma
Hansa Biopharma AB
Hansa Biopharma AB is a biotech organization headquartered in Lund, SE. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and U
Company details
- Status
- Public
- HQ
- Lund, SE
- Founded
- 2007
- Employees
- 136
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Idefirix 11 mg powder for concentrate for solution for infusion
Phase 3 · small molecule · End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant
Idefirix 11 mg powder for concentrate for solution for infusion for End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant is a Phase 3 program (small_molecule) at Hansa Biopharma AB with 1 ClinicalTrials.gov record(s).
Internal code 20-HMedIdeS-19
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hansa Biopharma AB
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant
- Status
- active
- Trials
- 1